Latest / Zero Friction / Delphistem: Dr. Noel Moya & Danae Moya

Transcript

Delphistem: Dr. Noel Moya & Danae Moya · Zero Friction

• Terry Coutsolioutsos/RevRx AI: well, welcome to the Zero Fiction podcast today. I have the wonderful opportunity to be with guests. My first two guests actually interview that I've done, which is very They are from ⁓ a groundbreaking technology company called Delphi STEM. And they are a husband and wife pair, number one, which makes them a really unique, powerful team. So I have Danae Moya, who is the chief operating officer for the company. And then we have Dr. Noel Moya, who is the chief science and technology officer. Together, they are trying to break a historical norm of having chronic diabetes really be a bad problem. And they're trying to bring a simple solution to make a big impact on a big problem. So I'm gonna turn it over to you two for a quick introduction on yourselves because I think that's a great story. And then tell us a little bit about the company. Dr. Noel Moya, PhD: Yeah. Hi. Thank you for having us on. I'm Danai. So I was born in Greece to a family of entrepreneurs and financial and accounting consultants. I came here to the US when I was 16. I finished high school college in Michigan. And from there, I went back to Europe. In the beginning, I was in London. I did my first masters. Then I relocated to Dubai in the UAE, where I stayed all together for almost 10 years. ⁓ at the same time my MBA with London Business School and a program here at Columbia Business School. And then a professional opportunity brought me to Germany. That's where I met Dr. Noel. And ⁓ of my career I've been in the ⁓ world, working in different roles in marketing strategy, communications, you name it. And ⁓ learning about ⁓ stem cell technology and science was really fascinating to me. So when I understood more about the life saving potential of stem cell technology and the way Noel shared his biomedical vision with me, it really resonated. So we decided to merge our skill set and create DelphiSTEM together. But I will pass it on to Noel to tell us about his background before we tell you more about DelphiSTEM. Thank you. Thank you so much. And thanks for having us here, Dary. So yes, my name is Noel Noya. I'm a scientist, stem cell scientist. founder of Delta STEM. my story started in Cuba, ⁓ country of Cuba, 90 miles from Florida. I was born there and into a family of medical doctors. So both my parents were medical doctors and my grandfather was a dentist actually. So growing up and talking about medicine and about the healthcare was very common for me. so I started medical school in Cuba at the age of 16 and a half and I finished five years out of six years from But due to the political instability in Cuba, communism, my family have to migrate into the US, into Miami, Florida, but I have to restart my high level education. So for that, went for a bachelor's degree in Upstate New York, Buffalo, New York, and I got exposed there to stem cell ⁓ a little bit and genetics a little bit. And that kind of chipped my future career into medicine, towards more like a science and scientific work. After my bachelor's in biology, I moved to San Diego, California, where I worked at several ⁓ institutes there, like ⁓ and La Jolla, I worked at the Salk Institute, and mainly University of San Diego UCSD. So there I did a lot of work in ⁓ iPSCs in these pre-reported stem cells from different epithelial cells, and I was able to differentiate these ⁓ stem cells. towards different cell types, mainly heart cells. I did a lot of lung cells and brain cells. I was able to generate several type of neurons, like cholinergic and glutamatergic neurons that were important. We were doing some studies with Alzheimer's and Parkinson's disease with this work. So all of that work in San Diego yield several good scientific publications and that motivated me to pursue a PhD. For that I went to Munich, Germany, south of Germany, and I was there for seven years, working really hard, including weekends, and I was able to do the differentiation towards the cells that produce insulin in the pancreas, so the meta-cells of the pancreas. I was able to use some of the protocols, 3D in suspension protocols ⁓ that I using in California and adapted to pancreatic protocols and I was able to... generate more cells and better quality of cells there. And all of that yield that I was able to graduate with honors magna cum laude and I was able to do screenings with the cells and ⁓ able to find different hormones and neurotransmitters that make ⁓ ⁓ more effective. So in Germany, I met Danai and we talked a lot about the possibility to bring this technology to the public. We were like, We need to help the people. We need to bring this to the public and move away from academia a little bit. So after Germany, we moved to Atlanta, Georgia. When I was working here at Emory University, I was doing a project differentiating cells towards the heart in order to make the cardiomyosides of the heart for biological pacemaker for kids. And around 2021, we decided to... open star gel system. And so we are now we have a beautiful genetic lab and a very nice stem cell lab here on ⁓ site. And we like excited and moving forward to our main goals. Terry Coutsolioutsos/RevRx AI: That's awesome. So you met in Munich and you spent seven years in Germany. Wow. That's a great scientific community, by the way. I spent a few years working for Siemens, who's based out of Germany as well. So I have a great deal of appreciation for the technology and how it's supported in Germany. So what a wonderful experience that might have been. So tell me a little bit about the company, what you're doing, how did you sort of come about the concept of the company, how did you, I know there's a little story behind the name of the company, so give us a little background. Dr. Noel Moya, PhD: Yeah, so the vision is big. envision using this technology, stem cell technology, to help with ⁓ diseases. We want to eliminate diseases that are caused by ⁓ biological aging and as we call it, and tear. And we want to start with diabetes. And it makes sense for several reasons. ⁓ we have one of the few experts in the world in house, Dr. Noel is really an expert in this. been doing it for over 10 years ⁓ and really his expertise is unmatched. But also it's quite a big market as we call it in business terms. And what that means is that there is a lot of people that are either diagnosed with diabetes or pre-diagnosed, have pre-diabetes or they're on their way to have it. It's been one of the fastest growing diseases in the world. At the moment there's over 38 million people in the U.S. over half a billion people in the world. ⁓ just want to use this technology and help cure the disease to the core. That's why the vision is big, but the focus at the moment is one disease at a time, starting with diabetes. Terry Coutsolioutsos/RevRx AI: great. so, so tell me a little bit about how did the name come about? Because I know you have a Greek background and I see the Delphi back there so I didn't know if there's a connection in any way. Dr. Noel Moya, PhD: Yeah, and you you spotted right. the name came about when, you know, when any company ⁓ in the beginning stages of being formed, you spend hours brainstorming and one will brainstorming for the name. We wanted something that would capture the essence of our vision. ⁓ ⁓ now is also ⁓ history of his another and he appreciates history ⁓ especially Greek and Roman, if I can say that. ⁓ And I, as you called it right, I'm from Greece. there is the, for those who don't know, there is the famous Oracle of Delphi. And back in the day in the ancient times, this was a place where people would go and seek advice or ask a question to get some guidance and insight in how to go about an important decision in their lives. So the way we envision is, you know, taking this concept, this element of the oracle of like letting gods you in the right way, but with a twist of using modern day technology and science. And hope we think that using science and ⁓ stem cell specifically can help guide people into taking ⁓ better care their health and improving their health. And obviously the second part to that stem comes from ⁓ stem cell ⁓ That's how we combined it. And as you noted, very well spotted, we use the Greek letter phi for the Delphi part to make that connection and pay homage to Greece. Terry Coutsolioutsos/RevRx AI: That's awesome. so, right, and diabetes is always, it's a big problem and it's getting bigger too. So that's the other part about this big problem is that it doesn't seem like anything is really starting to sort of get in the way of actually the disease. You can fix symptoms, right? But you're having a hard time curing the disease and the implications are ⁓ quality life, you know. shorter lifespans, all these and all the things that come with diabetes, with the cardiovascular issues, with the dementia issues, you know, they stem into our society in every direction. And so, so why don't we start with a little bit maybe like about the technology, right? About the technology itself. I know that there's, and my next questions are, me about what's going on in the marketplace today. What, what is the current standard of care? And then what is different about this, really is going to change the way diabetes care is going to be considered moving forward. Dr. Noel Moya, PhD: Yes, excellent. I'm glad you brought this up. So as of today, it's all about managing symptoms, It's essentially have type, if you have type 1 diabetes, means like your beta cells are depleted as a result of immune system imbalance, using terms, then you don't a production of insulin. And so you have to, the treatment is with insulin injections. Nowadays they have fancy pumps that they can put in the arm and they, every 10, 15 days, you have to replace it, but they just pump in insulin as you need it. In the case of type 2 diabetes, very simple terms too, you have something happen and then the muscles in the liver is called insulin resistance that lead to same problem, damaging of the beta cells. And then you will have at the beginning of the disease kind of a little bit high levels of insulin in blood, but eventually you will end up in the same place that type 1 ends up having no insulin because your beta cells are depleted. So the solution for type 2 is auto-medication at the beginning and then eventually auto-medication plus insulin injection. So everything that I have mentioned is managing symptoms, right? You don't... goal and solve the core issue. So, yeah, essentially, so what do we do with our technology? We are focusing on type 1 diabetes for now. We are basically focusing on that one. And what we do is essentially replacing the cells that are damaged. So that the new system will damage the beta cells. Beta cells now produce insulin. So we're bringing the cells back from the same body, from the individual's body. We're using a 3.5 centimeter diameter. polymer polish with the cells and that goes subcutaneous, to transplant. And ⁓ speaking, these cells inside the polish will get ⁓ vascular eyes and innervator, vessels and nerves will get inside and they will connect with the body and they will sense ⁓ time that the glucose fluctuates. So if you have a big meal, your glucose levels will increase in your blood and this ⁓ will, the cells inside the device will sense. ⁓ and it will secrete the insulin that you need. It's just exactly like the pancreas does. It's exactly like the way we were born. So that's how it works. the difficulty is to keep immune system out of this pouch. That's the main goal, essentially. And this is where a lot of white hairs are coming out because of that particular. Terry Coutsolioutsos/RevRx AI: Hahaha Dr. Noel Moya, PhD: that particular stage, but we're there. We're very excited with the technology that the powers have and super excited. We cannot share a lot of that. That's the secret. So. Terry Coutsolioutsos/RevRx AI: Okay. Well, do you have anything to add, Dr. Noel Moya, PhD: Yeah, I think it's also important to know that a lot of the efforts that have happened have already taken place in the market has pave the way, but also has helped bring to light some challenges that maybe you wouldn't think you'd come across. So that has been ⁓ very helpful creating the path towards a real cure. But I think, as Val mentioned, we have a few advantages in our favor. And using, I don't know if you want to share the fact that by using from the same person cells, the treatment that really, really helps increase the chances of the treatment ⁓ being So we're very excited. ⁓ Terry Coutsolioutsos/RevRx AI: Yeah, that's amazing. And that's one of the things I noted off the website as well is that, you you are using the patient's own cells. And I think, you know, a lot of times when you're introducing new things to the body, can, you know, they can either attack it or they can accept it. Right. And so, you know, you're, you're eliminating probably, you're mitigating a lot of that risk. And it's my guess is that, you know, very rarely is the body going to reject their own cells again. So that's probably a wonderful opportunity for patients. And then the other thing I realized too is that there's a lot of drugs that come with the introduction of foreign body as well. you're like, you know, you're, there's a lot of variables that go into foreign body acceptance into the body. And so think that there's a lot of uniqueness to that as well. And that's probably some of the that you're pitching to investors and to maybe strategic, you know, investors as well as why this is a different. What makes this different versus others, right? Dr. Noel Moya, PhD: Yeah, that is correct. So a company launched a clinical trial a few years back and essentially what they did, they generate the cells that we can generate here in our lab, the beta cells that produce insulin and they transplant it into patients, but ⁓ these patients in immunosuppressant drugs. And ⁓ is not ideal, obviously not because any infections can ⁓ you, right? So that's something that we try to circumvent, try to avoid that. And that's why the Pouch, and that's why the Pouch has the technology it has to keep the immune system away from the cells. But at the same time, you don't have to use immunosuppressors. So that's our winning card, essentially. Terry Coutsolioutsos/RevRx AI: leads me to a question around economics, just knowing like from an economic perspective, I think we have a great healthcare system in the United States, but I think it's broken economically. think that, you know, so how does, you know, Delphi Stem contribute to a more viable economic outcome as well for ⁓ chronically diseased patient that, you know, probably is going to cost the healthcare systems maybe millions of dollars over a lifetime. Dr. Noel Moya, PhD: Yeah, and that's a really good point. And that has been something that we've been talking about since the beginning of the inception of this project, because the reality is that diabetes alone contributes something like $900 billion to the health care system in different ways. Over the course of a diabetic patient's lifetime, they spend over half a million dollars towards the medicine and the things that they need to treat this disease. mentioned that in terms of economics, it doesn't make sense from any angle because it constant supply of medication and there is also the risk of ⁓ injections that could go wrong. There's other things with that. And as a chronic disease, ⁓ also mentioned earlier, ⁓ doesn't remain stable. It deteriorates over time. And then all the other complications that come from it, like heart failure, kidney disease, also kind of pile on problem of managing the disease. So the way we're looking at this, and in the beginning stages, we use kind of like a design thinking methodology, which in simple terms means how can every stakeholder in this benefit from this? So ⁓ you know, the healthcare system would benefit by having more targeted treatments that are really curing the problem, and they could repurpose their... their budgets that are being absorbed in diabetes towards something else that can really help overall healthcare ecosystem. From our perspective, and will not ⁓ get details, but we are kind of, we're a vertically integrated business model, meaning we're trying to do most of the things in-house, which helps do things faster and more economically, both for us as we're creating the treatment, but also for the end user, for the patient, because we hope that when the treatment will come to market, everybody can afford it, whether through their insurance or if they choose to out of pocket. That is our vision, to make this as widely accessible as possible so that every diabetic person can have access to it. Terry Coutsolioutsos/RevRx AI: That's awesome. So where do you stand today with the technology and what is the path forward in getting it into the hands of caregivers and facilities? Dr. Noel Moya, PhD: Yeah, you want to speak to the technology? Yeah, with the technology, feel, I mean, we feel very happy and confident with the technology. Like I say, big companies that have access to a lot of resources, they just are not doing so great with the technology. I have to politely say that and very politely. And also we're very grateful because they opened the door for us to walk behind, right? They, they. They started clinical trials in humans, so they kind ⁓ their way for the FDA ⁓ we can walk behind. So I'm very grateful. But technologically speaking, the using of immunosuppressants is not a, I see as a positive thing ⁓ at all. So on that regard, the fact that we are developing everything ⁓ with that in that gives us a huge advantage. So that's why we are extremely positive to test everything that we have so far and be able to do clinical trials. We're about to jump into big clinical trials to do some testings and then eventually do more clinical trials to do some more testing. Essentially, we need human trials to do the testing with the immune system that we need to do. So, but it's a very safe device, if I can put it in a word, because like I say, it's a polymer. So if something goes wrong, it will not work. It will not just, it will not work but not having any serious consequence on the person, right? we feel ⁓ with that one too. Terry Coutsolioutsos/RevRx AI: So is there a trial around the corner? Is that why we're fundraising right now? So give us a little update on like, you know, is there clinical trials sort of on your milestones and a timeframe? You know, what do you need to get there? That kind of thing. Dr. Noel Moya, PhD: Yeah, great. So yeah, in terms of the timeline, we're of in this inflection point. So when we ⁓ started the company, you know, we dedicated a lot of time and all of our resources into the scientific work that took place in the lab. Then was ⁓ the animal kind of study that we did in mice. We had really successful results. did really well there and we got the results that we wanted and encouraged us to move to the next stage. ⁓ Now we are, we've done all the prep work and we are just about to start our preclinical trial, which, you know, the FDA requires and it requires the typical path. do large animal models, which is pig, the closest to humans in anatomy, and then human clinical trials, and then you hit the market. So that's why we're kind of in this inflection point right in the middle of our path. everything ⁓ ready for the preclinical trial. Typically companies are stays funded by federal grants at the moment to fund this part of the studies. There been some delays with the legislation. I think five or six months. However, it got signed into law. I think exactly a week ago, so we're very hopeful that exactly that was that was a cause for celebration for many companies last week. However, we didn't want to just sit and wait. ⁓ We just started communicating public. Terry Coutsolioutsos/RevRx AI: That's awesome, congratulations. Yeah, good. Dr. Noel Moya, PhD: out for kind of a bridge round. We're fully angel funded at the moment. Everything that we have accomplished to this day has been thanks to angel investors that truly believe in the mission and the vision and they believe in the cure of this disease. So we've extended this into a bridge round and communicating to anybody that this resonates with if they want to come on board because the quicker we get through the preclinical trial, the quicker we will get through the human clinical trial and the quicker we will hit the market. So this is kind of an open invitation if any of your listeners ⁓ ⁓ interested in learning more to get in touch with us as well. Terry Coutsolioutsos/RevRx AI: We definitely will. And so what does this raise look like for you? Like, what are you looking for in terms of an amount? Dr. Noel Moya, PhD: Yeah, the we're focusing the bigger part of the bigger round is a peak clinical trial. So we're focusing on the $750,000 at the moment. We've had angels that have come on with 50k, 100k, whatever is the amount of comfort because investment from an angel can really move the needle towards getting closer to the big trial. Terry Coutsolioutsos/RevRx AI: Yeah, and if you thought about family offices, well, I know that there are family office out there looking for a unicorn and it sounds like you definitely have unicorn potential for sure, right? Like if this works, this is one of those things that can go from zero to 100 miles an hour pretty fast, right? Dr. Noel Moya, PhD: 100 % and you got that right. You keep the nail on the head with this because there are family offices. Well, it seems that it resonates with you. So you should join our pitching efforts. No, but you know, it's true though, because the family offices, one of the things that we find very interesting is that they really, there's this kind of interesting combination between having the funds available, but looking for impact and looking for something that can make a difference. Terry Coutsolioutsos/RevRx AI: You need to take me around to do some pitching with you now, see? We'll get our going. There we go. Dr. Noel Moya, PhD: And generally they all kind of have a mission to the effect of we want to contribute to improving the humanity and making the world a better place and the kind of mission that aligns with ours. So family offices are definitely aligned with what we're doing. It's just really hard to on doors and them to open, like, ⁓ let's talk. But either any family offices that ⁓ are in your listening. audience we would love to talk to because the ones that have come on board have been truly and champions and ambassadors in our ⁓ So we love that. Terry Coutsolioutsos/RevRx AI: Well, and I think family office has a great angle, especially with your technology and just understanding that, you know, I argue that any family that exists in America today has had somebody in their family being impacted by diabetes one way or the other, right? So you don't have to look very far see negative implications in your life, whether it's a family member or a dear friend. You know, we all have people that have had that complication. And so like for me, when I hear about what you're doing and actually looking at it from a curative perspective versus a symptom treatment perspective is really, you know, refreshing and what a great opportunity in terms of moving forward and how healthcare is designed for certain chronic diseases. you we all have this sort of vision one day, we, if you grew up watching Star Trek as a kid, which was a science fiction show. ⁓ would put your body and wave a wand over your body and they would fix whatever happened, right? And so this seems to me like one of those opportunities where if you have this type of therapy that you've waved that magic wand over the patient and you are creating an opportunity to fix what is a disease for a lifetime. what a wonderful mission and purpose to wake up and get to do every day too. So you have that privilege as well doing that. What a wonderful thing. Dr. Noel Moya, PhD: It is absolutely. And like you said, I think we're living in a special, times that we have so much technology that can help us to get there. And this is unique, right? mean, 10, 20 years ago, we didn't have it. So it's very, we need to take advantage of this and move forward and help and try to get to the finish line with our goals. And yeah, it's really nice. It's really exciting what we do. It's really exciting that you can. I wake up like you say every day, try to help a lot of people that, I mean, somebody has type 1 diabetes, have to inject every day. That's not fun. ⁓ have to, you know, you have to even now with this fancy pads you put on your arms, you have to shift every 15 days. Terry Coutsolioutsos/RevRx AI: even a metronic device, even a metronic, you know, artificial pancreas device, even those things are not, you're still putting implants into people's bodies. You're still introducing foreign bodies and I think a lot of technologies out there are treating symptoms and, but again, curing the disease is a whole different angle. So what has been like, what's been the fastest thing? What was the easiest thing that you accomplished through this process so far? like, what was like, wow, that was easier than I thought it was going to be. Dr. Noel Moya, PhD: Nothing has been easy. Nothing has been easy. I think the science part, I've seen him motivated in the lab working with his own machine, his own equipment. I think that has been probably the least challenging aspect of building that process. It's big task. You're creating a knot of Terry Coutsolioutsos/RevRx AI: Or has it all been hard? Kind of it's been easy. Okay. Dr. Noel Moya, PhD: I mean, this is not a software company that you can work from garage of your car into your laptop, right? You need equipment that are not, that are expensive and you need all, you need a space with special and special things. And so everything else is being a lot of work. But like I say, the end result is ⁓ worth the sacrifice worth because the end result would be amazing. And that we're very, very confident in our technology, very confident that we can deliver it and get to the finish line. And that's what, that would sort of keep us going and keep us motivated every day. But ⁓ excited, exciting work even something that you like, but I'm crazy. There's a lot of challenges from the financial ⁓ ⁓ ⁓ Terry Coutsolioutsos/RevRx AI: No. So is the financial aspect the biggest friction point for you now to get moving forward, you think? Dr. Noel Moya, PhD: I think so. Absolutely. Financial is the biggest because the more funds you have, the faster you can go. Right? So there's a correlation there. yeah, our speed is limited with the... Terry Coutsolioutsos/RevRx AI: Okay. maybe there's some things we can do to work together on, you know, trying to find new ways and new angles to at, you know, finding funds as well. you know, maybe there's some discussions can have after the podcast and, but again, back to the podcast, back to your company and your mission. So, ⁓ your... two years, three years, five years, what is your milestone to market if you were to get all the money that you needed now, right? So if you got your three quarter of a million to your million dollars, you could finish your pig lab study, right? Is that what I'm gathering? And then you wait for the results for that. And then you can begin a first in human activity, I'm guessing, which is a small little safety study, you know, probably. Dr. Noel Moya, PhD: Yep. Yep. You got that right? So yeah, the path forward and maybe if I can add quickly on the point we were just talking about before, you you were looking for something that has been easy that we were not able to answer that. But I will tell you something. in constant ⁓ kind like challenging position when you build a new company, and I'm sure that would resonate with you and maybe with other listeners is that it kind of forces you to become extremely lean. extremely focused, extremely intentional with everything from your time to the little resources, the little funds you have. So I think going through that constant exercise of like reprioritizing and refocusing and being lean has definitely been beneficial because the point we're in now, the inflection point as we call it has enabled us to really be focused on what do we need to get done. with what is the littlest possible that we need to move forward to the next milestone. And we're able to do this and we're able to focus and say out of the entire round, as soon as we hit the 750K mark, we're gonna go ahead with a preclinical trial because we know that data will help us get to the milestone after that. So maybe not an easy part, but the lesson from this experience has been very beneficial to us. if I may add, it kind of like, validates your purpose and your mission because many people can give up when things get tough. if you keep going, that means that you really, believe in the ⁓ and what you're on ⁓ ⁓ up in the morning and be like, no, I need to keep going because this needs to happen and we need to bring it to the finish line. So just wanted to add that into the. ⁓ agree with that. I think also, yeah, a little bit more positive view that you learn a lot by being an entrepreneur. Terry Coutsolioutsos/RevRx AI: Yeah. Dr. Noel Moya, PhD: I think your life, you learn a lot from life or what is life about by being an entrepreneur because you put yourself in positions very, very scary for a lot of normal people. A lot of people will be so scary, like what do you mean? Terry Coutsolioutsos/RevRx AI: being an entrepreneur, right? Like it's, you know, there a of vulnerabilities that come with that. Dr. Noel Moya, PhD: I'll like you have funding for like six months. What's going to happen after that? How do you pay for this? How do you pay for that? But then, you know, more funding comes in and then things keep moving forward. But that I think learn to lose your fear. You learn to live ⁓ like, hey, you know, I will figure out something. But ⁓ mission is to get there is our goal. And we are going there and everything will align in that. ⁓ Surprisingly, everything aligns. It's actually surprisingly, but everything aligns. So you lose your fear and you keep going forward. And I think that's definitely a benefit of I think entrepreneurial life and starting something from scratch, starting something that you don't have a nest of, like the protection nest or anything. So that's a ⁓ Terry Coutsolioutsos/RevRx AI: I think it's wonderful and it leads me to my next question for both of you. you know, it's I want to get an answer out of both of you and it's sort of it's a closing question that I ask every guest. All right. And it's a bit of a surprise. So I'll let you go slowly so you can start thinking about but you know, thinking about yourself today and if you were to go back and want to give yourself advice, whether it was. 18 years of age or 22 years of age, whenever those sort of points in your life when you can turn right or turn left, right? Like that really kind of dictate what happens to you for the rest of your life. So what advice would you give yourself, your 22 year old self from your experience today? And so I'll start with you, Dene. you know, because you've had a lot of inflection points in your life. So it'd be interesting to see what you come up with. Dr. Noel Moya, PhD: I love this question. you know, whenever a similar question comes up in any conversation, I always think back to the Steve Jobs commencement speech in Stanford, where everything makes sense looking backwards and you connect the dots. ⁓ ⁓ a 22-year-old, yeah, thinking back, I think ⁓ in my personal life, I didn't understand why things went the way they went. But looking back now, I would say, my younger self and anybody who is 22 years old now, whatever comes your way, do it to the best of your ability, give it your all learn every experience because at 22 you will not know what is your fuller purpose and path in life, but it would be a connecting dot when you get to it and it will all make sense when you get to that point because ⁓ my was not in science, it was not in the medical world. I was in different parts of Terry Coutsolioutsos/RevRx AI: Yeah Dr. Noel Moya, PhD: different industries, but the skills that I acquired with every experience and every company and every, every title I had sense because it helped me to where I am ⁓ today and help with my skillset merging with another skillset and bring this to life and help people and make a difference. So trust your path, do the best you can and just faith that it will all make sense ⁓ in the end. Terry Coutsolioutsos/RevRx AI: What a great answer, thank you for that. Noel, how about you? Dr. Noel Moya, PhD: you. That was such a good answer. don't know how I can match that. But for me, will say that life is such a beautiful experience. And we are all here to experience these things. Sometimes it's pain, sometimes it's happiness, but both are experiences that to experience. ⁓ Terry Coutsolioutsos/RevRx AI: She puts you on the hot seat, Dr. Noel Moya, PhD: If I go back in my 20s, I will say to myself, don't worry, don't be afraid, just follow your heart, follow your gut and keep moving forward that everything is going to be fine. And that's something that I say to myself today too. Everything will be fine as long as you're the right thing, as long as you are trying to help, are an honest person and you are a good person, everything, life will always smile at you. You just have to do the task and wake up and do it. And if you're tired, you know, keep doing it. Keep doing it. if a door closes, you knock other doors and keep doing it. And eventually the bathroom open and your goal will be achieved. And then you have to find another goal because that's what life is about. It's not about to see drinking a margarita by the pool. That's not what it's about. You can do that too. That's great. That's fun. We all love that. But it's about, it's about Terry Coutsolioutsos/RevRx AI: Yeah. Yeah Dr. Noel Moya, PhD: finding a task, getting in there, solve the problem and hope that the problem that you're solving will benefit a lot of people. So that's ⁓ I see it and I will say that to ⁓ in my ⁓ and today too because I mean, still a long path to go. Terry Coutsolioutsos/RevRx AI: That's awesome. one of things that you struck with me in your conversation today was without fear. And I think that's what heard from you as well. ⁓ What great sentiment for everybody. So ⁓ thank both. What a wonderful opportunity. And you guys bring such great energy. I wish you nothing but the best in the future. And thank you for having the opportunity, for giving me the opportunity to learn more about yourselves as humans and as more about your company with. with Delphi STEM as well. Dr. Noel Moya, PhD: Thank you for having us. Thank you so much, Terri, for having us. Terry Coutsolioutsos/RevRx AI: Thank you guys.